NCT07307131

Furosemide-Digoxin vs. Polidocanol for Cutaneous Warts

A Head-to-Head Comparison of Intralesional Furosemide-Digoxin Versus Polidocanol for the Treatment of Cutaneous Warts With 6-Month Follow-up

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 64 (actual)
• Sponsor: Benha University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study compares the effectiveness and safety of two different intralesional treatments for cutaneous warts: a combination of furosemide and digoxin versus polidocanol.

Detailed description

This is a prospective, randomized, single-blind, comparative clinical study to evaluate the efficacy and safety of intralesional combined furosemide-digoxin versus intralesional polidocanol in the treatment of cutaneous warts. Sixty-four adult patients were randomized to receive one of the two treatments every two weeks for a maximum of four sessions. The main goal was to see which treatment was better at completely clearing the warts. The study also looked at side effects and how often the warts came back within six months.

Conditions

• Cutaneous Warts
• Human Papilloma Virus (HPV)

Interventions

Type	Name	Description
DRUG	Intralesional combined furosemide (10 mg/ml) and digoxin (0.25 mg/ml)	Group A (Experimental): Intralesional combined furosemide (10 mg/ml) and digoxin (0.25 mg/ml)
DRUG	Intralesional polidocanol 2%	Group B (Active Comparator): Intralesional polidocanol 2%

Timeline

• Start date: 2024-09-01
• Primary completion: 2025-03-01
• Completion: 2025-09-30
• First posted: 2025-12-29
• Last updated: 2026-01-02

Locations

1 site across 1 country: Egypt